Developing a European research network to address unmet needs in anxiety disorders

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 10, 2013, Pages 2312-2317

  Baldwin, David S ^a   Pallanti, Stefano ^b   Zwanzger, Peter ^c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Anxiety disorders; Costs; Impairment; Public health

Indexed keywords

ANXIETY DISORDER; CAUSAL ATTRIBUTION; CLINICAL FEATURE; COGNITIVE THERAPY; CULTURAL FACTOR; EVIDENCE BASED PRACTICE; HUMAN; MEDICAL RESEARCH; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIORITY JOURNAL; PROGRAM DEVELOPMENT; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; SOCIAL PHOBIA; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT PLANNING;

ANXIETY DISORDERS; COSTS; IMPAIRMENT; PUBLIC HEALTH;

ANXIETY DISORDERS; EUROPE; HEALTH CARE COSTS; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INTERNATIONAL COOPERATION; PREVALENCE;

EID: 84890161145     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.01.009     Document Type: Review

References (56)

1. Altamura A.C., Dell'Osso B., D'Urso N., Russo M., Fumagalli S., Mundo E. Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder. CNS Spectrums 2008, 13:415-422.
2. Baldwin D.S., Stein D.J. A joint European and South African research network in anxiety disorders (editorial), 2012. Human Psychopharmacology Clinical 2012, 27:4-5.
3. Baldwin D.S., Stein D.J., Dolberg O.T., Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder?. An exploration of the randomised controlled trial database. Hum. Psychopharmacol. Clin. Exp. 2009, 24:269-275.
4. Baldwin D.S., Allgulander C., Altamura A.C., Angst J., Bandelow B., Den Boer J., Boyer P., Davies S., Dell'Osso B., Eriksson E., Fineberg N., Fredrikson M., Herran A., Maron E., Metspalu A., Nutt D., van der Wee N., Vázquez-Barquero J.L., Zohar J. Manifesto for a European anxiety disorders research network. European Neuropsychopharmacology 2010, 20:426-432.
5. Baldwin D.S. Where is the room for improvement in the drug treatment of depression and anxiety?. Hum. Psychopharmacol. Clin. Exp. 2011, 26:1-3.
6. Baldwin D.S., Schweitzer E., Xu Y., Lyndon G. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?. European Neuropsychopharmacology 2012, 22:137-142.
7. Baldwin D.S., Waldman S., Allgulander C. Evidence-based pharmacological treatment of generalized anxiety disorder. International Journal of Neuropsychopharmacology 2011, 14:697-710.
8. Bandelow B., Zohar J., Hollander E., Kasper S., Möller H.J. WFSBP task force on treatment guidelines for anxiety obsessive-compulsive post-traumatic stress disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World Journal of Biological Psychiatry 2008, 9:248-312.
9. Beesdo K., Jacobi F., Hoyer J., Low N.C., Hofler M., Wittchen H.U. Pain associated with specific anxiety and depressive disorders in a nationally representative population sample. Social Psychiatry and Psychiatric Epidemiology 2010, 45:89-104.
10. Behrendt S., Beesdo-Baum K., Zimmermann P., Hofler M., Perkonigg A., Buhringer G., Lieb R., Wittchen H.U. Psychological Medicine 2011, 41:1073-1085.
11. Berlin H.A., Koran L.M., Jenike M.A., Shapira N.A., Chaplin W., Pallanti S., Hollander E. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. Journal of Clinical Psychiatry 2011, 72:716-721.
12. Boschloo L., Vogelzangs N., Smit J.H., Van Den Brink W., Veltman D.J., Beekman A.T., Penninx B.W. Comorbidity and risk indicators for alcohol use disorders among persons with anxiety and/or depressive disorders: findings from the Netherlands Study of Depression and Anxiety (NESDA). Journal of Affective Disorders 2011, 131:233-242.
13. Dahlhoff N., Siegmund A., Golub Y., Wolf E., Holsboer F., Wotjak C.T. AKT/GSK-3beta/beta-catenin signalling within hippocampus and amygdala mediates genetically determined differences in posttraumatic stress disorder like symptoms. Neuroscience 2010, 169:1216-1226.
14. Dell'Osso B., Buoli M., Hollander E., Altamura A.C. Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder. World Journal of Biological Psychiatry 2010, 11:59-65.
15. Diemer J., Vennewald N., Domschke K., Zwanzger P. Therapy-refractory panic: current research areas as possible perspectives in the treatment of anxiety. European Archives of Psychiatry and Clinical Neuroscience 2010, 260(Suppl. 2):S127-S131.
16. Dold M., Aigner M., Lanzenberger R., Kasper S. Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomised, placebo-controlled trials. Fortschritte der Neurologie-Psychiatrie 2011, 79:453-466.
17. Domschke K., Deckert J. Genetics. Current Topics in Behavioral Neurosciences 2010, 2:63-75.
18. Domschke K., Dannlowski U. Imaging genetics of anxiety disorders. NeuroImage 2010, 53:822-831.
19. de Klerk S., Van Noorden M., van Giezen A.E., Spinhoven P., den Hollander-Gijsman M.E., Giltay E.J., Speckens A.E.M., Zitman F.G. Prevalence and correlates of lifetime deliberate self-harm and suicidal ideation in naturalistic outpatients: the Leiden Routine Outcome Monitoring study. Journal of Affective Disorders 2011, 133:257-264.
20. Fava G.A., Porcelli P., Rafanelli C., Mangelli L., Grandi S. The spectrum of anxiety disorders in the medically ill. Journal of Clinical Psychiatry 2010, 7:910-914.
21. Fineberg N.A., Potenza M.N., Chamberlain S.R., Berlin H.A., Menzies L., Bechara A., Sahakian B.J., Robbins T.W., Bullmore E.T., Hollander E. Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. Neuropsychopharmacology 2010, 35:591-604.
22. Garner M., Möhler H., Stein D.J., Mueggler T., Baldwin D.S. Research in anxiety disorders: from the bench to the bedside. European Neuropsychopharmacology 2009, 19:381-390.
23. Gili M., Comas A., Garcia-Garcia M., Monzon S., Antoni S.B., Roca M. Comorbidity between common mental disorders and chronic somatic diseases in primary care patients. General Hospital Psychiatry 2010, 32:240-245.
24. Geschwind N., Peeters F., Jacobs N., Delespaul P., Derom C., Thiery E., van Os J., Wichers M. Meeting risk with resilience: high daily life reward experience preserves mental health. Acta Psychiatrica Scandinavica 2010, 122:129-138.
25. Gloster A.T., Wittchen H.U., Einsle F., Hofler M., Lang T., Helbig-Lang S., Fydrich T., Fehm L., Hamm A.O., Richter J., Alpers G.W., Gerlach A.L., Strohle A., Kircher T., Deckert J., Zwanzger P., Arolt V. Mechanism of action in CBT (MAC): methods of a multi-center randomized controlled trial in 369 patients with panic disorder and agoraphobia. European Archives of Psychiatry and Clinical Neuroscience 2009, 259(Suppl. 2):S155-S166.
26. Gloster A.T., Wittchen H.U., Einsle F., Lang T., Helbig-Lang S., Fydrich T., Fehm L., Hamm A.O., Richter J., Alpers G.W., Gerlach A.L., Strohle A., Kircher T., Deckert J., Zwanzger P., Hofler M., Arolt V. Psychological treatment for panic disorder with agoraphobia: a randomized controlled trial to examine the role of therapist-guided exposure in situ in CBT. Journal of Consulting and Clinical Psychology 2011, 79:406-420.
27. Gradus J.L., Qin P., Lincoln A.K., Miller M., Lawler E., Sorensen H.T., Lash T.L. Post-traumatic stress disorder and completed suicide. American Journal of Epidemiology 2010, 171:721-727.
28. Gustavsson, A., Svensson, M., Jacobi, F., Allgulander, C., Alonso, J., Beghi, E., Dodel, R., Ekman, M., Faravelli, C., Fratiglioni, L., Gannon, B., Jones, D.H., Jennum, P., Jordanova, A., Jönsson, L., Karampampa, K., Knapp, M., Kobelt, G., Kurth, T., Lieb, R., Linde, M., Ljungcrantz, C., Maercker, A., Melin, B., Moscarelli, M., Musayev, A., Norwood, F., Preisig, M., Pugliatti, M., Rehm, J., Salvador-Carulla, L., Schlehofer, B., Simon, R., Steinhausen, H.C., Stovner, L.J., Vallat, J.M., den Bergh, P.V., Van Os, J., Vos, P., Xu, W., Wittchen, H.U., Jönsson, B., Olesen, J.; CDBE2010Study Group, 2011. Cost of disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 21, 718-779.
29. Hendrikson H., Prins J., Olivier B., Oosting R.S. Environmental enrichment induces behavioural recovery and enhanced hippocampal cell proliferation in an antidepressant-resistant animal model for PTSD. PLoS One 2010, 5:e11943.
30. Hou R., Baldwin D.S. A neuroimmunological perspective on anxiety disorders. Human Psychopharmacology: Clinical and Experimental 2012, 27:6-14.
31. Kessler R.C., Ruscio A.M., Shear K., Wittchen H.U. Epidemiology of anxiety disorders. Current Topics of Behavioral Neurosciences 2010, 2:21-35.
32. Lamb J.D., Bower P., Rogers A., Dowrick C., Gask L. Access to Mental Health in Primary Care: A Qualitative Meta-Synthesis of Evidence from the Experience of People from 'Hard to Reach' Groups. Health 2012, 16:76-104.
33. Lamers F., van Oppen P., Comijs H.C., Smit J.H., Spinhoven P., van Balkom A.J., Nolen W.A., Zitman F.G., Beekman A.T., Penninx B.W. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). Journal of Clinical Psychiatry 2011, 72:341-348.
34. Lewis-Fernandez R., Hinton D.E., Laria A.J., Patterson E.H., Hofmann S.G., Craske M.G., Stein D.J., Asnaani A., Lia B. Culture and the anxiety disorders: recommendations for DSM-V. Depression and Anxiety 2010, 27:212-229.
35. Martens E.J., de Jonge P., Na B., Cohen B.E., Lett H., Whooley M.A. Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Archives of General Psychiatry 2010, 67:750-758.
36. Meyer T., Buss U., Hermann-Lingen C. Role of cardiac disease severity in the predictive value of anxiety for all-cause mortality. Psychosomatic Medicine 2010, 72:9-15.
37. Norton J., de Roquefeuil G., David M., Boulenger J.P., Ritchie K., Mann A. Prevalence of psychiatric disorders in French general practice using the patient health questionnaire: comparison with GP case-recognition and psychotropic medication prescription. Encephale 2009, 35:560-569.
38. Nutt D., Goodwin G. ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP. European Neuropsychopharmacology 2011, 21:495-499.
39. Pallanti S., Bernardi S., Antonin S., Sing N., Hollander E. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. CNS Drugs 2009, 23:1047-1055.
40. Pallanti S., Bernardi S. Neurobiology of repeated transcranial magnetic stimulation in the treatment of anxiety: a critical review. International Clinical Psychopharmacology 2009, 24:163-173.
41. Pan C., Pfeil, B.S., 2002. Minderheitenrechte in Europa. Handbuch der europäischen Volksgruppen. English translation, 2004.
42. Pego J.M., Sousa J.C., Almeida O.F.X., Sousa N. Stress and the neuroendocrinology of anxiety disorders. Current Topics in Behavioral Neurosciences 2010, 2:97-117.
43. Pinto-Meza A., Fernandez A., Bruffaerts R., Alonso J., Kovess V., De Graaf R., de Girolamo G., Matschinger H., Haro J.M. Dropping out of mental health treatment among patients with depression and anxiety by type of provide: results of the European Study of the Epidemiology of Mental Disorders. Social Psychiatry and Psychiatric Epidemiology 2011, 46:273-280.
44. Prins M.A., Verhaak P.F.M., Somlders M., Laurant M.G.H., van der Meer K., Spreeuwenberg P., van Marwijk H.W.J., Penninx B.J.H., Bensing J.M. Patient factors associated with guideline-concordant treatment of anxiety and depression in primary care. Journal of General Internal Medicine 2009, 25:648-655.
45. Rhenbergen D., Batelaan N.M., de Graaf R., Nolen W.A., Spijker J., Beekman A.T., Penninx B.W. The 7-year course of depression and anxiety in the general population. Acta Psychiatrica Scandinavica 2011, 123:297-306.
46. Romera J., Fernandez-Perez S., Montejo A.L., Caballeor F., Caballero L., Arbesu J.A., Delgado-Cohen H., Desaiah D., Polavieja P., Gilaberte I. Generalized anxiety disorder, with or without comorbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health status. Journal of Affective Disorders 2010, 127:160-168.
47. Salomoni G., Grassi M., Mosini P., Riva P., Cavedini P., Bellodi L. Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response. Journal of Clinical Psychopharmacology 2009, 29:343-349.
48. Schneider A., Horlein E., Wartner E., Schumann I., Henningsen P., Linde K. Unlimited access to health care - impact of psychosomatic comorbidity on utilisation in German general practices. BMC Family Practice 2011, 18:12-51.
49. Sportel B.E., Nauta M.H., de Hullu E., de Jong P.J., Hartman C.A. Behavioral inhibition and attentional control in adolescents: robust relationships with anxiety and depression. Journal of Child and Family Studies 2011, 20:149-156.
50. Stein D.J., Baldwin D.S., Bandelow B., Blanco C., Fontenelle L.F., Lee S., Matsunaga H., Osser D., Stein M.B., van Ameringen M. A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Current Psychiatry Reports 2010, 12:471-477.
51. Strohle A., Graetz B., Scheel M., Wittmann A., Feller C., Heinz A., Dimeo F. The acute antipanic and anxiolytic activity of aerobic exercise in patients with panic disorder and healthy control subjects. Journal of Psychiatric Research 2009, 43:1013-1017.
52. Van Duinen M.A., Niccolai V., Griez E.J.L. Challenging anxiety: a focus on the specificity of respiratory symptoms. Current Topics in Behavioral Neurosciences 2010, 2:229-250.
53. Van Noorden M.S., Minkenberg S.E., Giltay E.J., Den Hollander-Gijsman M.E., Van Rood Y.R., Van Der Wee N.J., Zitman F.G. Pre-adult versus adult onset major depressive disorder in a naturalistic patient sample: the Leiden Routine Outcome Monitoring Study. Psychological Medicine 2011, 41:1407-1417.
54. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jonsson B., Olesen J., Allgulander C., Alonso J., Faravelli C., Fratiglioni L., Jennum p., Lieb R., Maercker A., van Os J., Preisig M., Salvador-Carulla L., Simon R., Steinhausen H.-C. The size and burden of mental disorders and other disorders of the brain in Europe in 2010. European Neuropsychopharmacology 2011, 21:655-679.
55. Zwanzger P., Fallgatter A.J., Zavorotnyy M., Padberg F. Anxiolytic effects of transcranial magnetic stimulation - an alternative treatment option in anxiety disorders. Journal of Neural Transmission 2009, 116:767-775.
56. Zwanzger P., Diemer J., Jabs B. Comparison of combined psycho- and pharmacotherapy with monotherapy in anxiety disorders: controversial viewpoints and clinical perspectives. Journal of Neural Transmission 2009, 116:759-765.